Annexuzlimab
Based on 1 Customer Validation
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.67%
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
Annexin A1/ANXA1
Annexuzlimab (MDX-124) (2.5-10 μM; 72 h) significantly reduces proliferation in a dose-dependent manner in ANXA1-expressing human cancer cell lines, with 10 μM causing >50% viability reduction in some breast and ovarian cell lines, but has no effect on non-ANXA1-expressing lung cancer cell lines[1].
Annexuzlimab (10-25 μM; 24 h) induces a dose-dependent G1 phase cell cycle arrest, with 25 μM causing the most pronounced effects (33.5% G1 increase in MDA-MB-231, 21.2% in A549, 10.8% in BxPC-3), and does not induce apoptosis[1].
Annexuzlimab (5 μM; 72 h) does not induce apoptosis in MCF-7 breast or Caco-2 colorectal cancer cells[1].
Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, HCC1806, MDA-MB-231, MCF-7/TAMR7, BxPC-3, MIA PaCa-2, PANC-1, A2780, A2780cis, A2780ADR, Caco-2, HCT116, SW480, NCI-H69/CPR, A549, COR-L23, COR-L23.5010
-
Concentration:2.5-10 μM
-
Incubation Time:72 h
-
Result:Caused a significant dose-dependent reduction in cellular proliferation in all ANXA1-expressing breast, pancreatic, ovarian, colorectal, and some lung cancer cell lines compared to IgG1 isotype control; At 10 μM, MCF-7, HCC1806, and MDA-MB-231 had >50% viability reduction, MCF-7/TAMR7 had 21% reduction, BxPC-3 had 40% reduction, MIA PaCa-2 had 20% reduction, PANC-1 had 34% reduction, A2780 had 31% reduction, A2780cis had 48% reduction, A2780ADR had 72% reduction, Caco-2, HCT116, and SW480 had significant reduction, NCI-H69/CPR had 36% reduction, A549 had 37% reduction; Showed no anti-proliferative activity in non-ANXA1-expressing COR-L23 and COR-L23.5010 lung cancer cells.
-
Cell Line:BxPC-3, MIA PaCa-2, MDA-MB-231, A549
-
Concentration:10 μM, 25 μM
-
Incubation Time:24 h
-
Result:Induced a dose-dependent G1 phase cell cycle arrest compared to untreated control cells; At 25 mM, MDA-MB-231 had a 33.5% increase in G1 phase and 29.1% decrease in S phase, A549 had a 21.2% increase in G1 phase and 18.3% decrease in S phase, BxPC-3 had a 10.8% increase in G1 phase and 10.4% decrease in S phase; Did not induce apoptosis (no sub G0/G1 peak observed).
-
Cell Line:MCF-7, Caco-2
-
Concentration:5 μM
-
Incubation Time:72 h
-
Result:Showed no significant difference in the percentage of early or late apoptotic/necrotic cells compared to untreated control cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 9 weeks old, orthotopic inoculation with 4T1-luc murine triple-negative breast cancer cells)[1]
-
Dosage:1 mg/kg
-
Administration:i.v.; two doses on day 1 and day 8
-
Result:Significantly inhibited tumour growth versus vehicle control, achieving 23% tumour growth inhibition by day 15. Observed no noticeable change in body weight throughout the study.
P04083
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
Synonyms
MDX-124
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz